At Klarisana we are committed to making Ketamine Therapy accessible to the largest number of patients possible

Being one of the pioneers in the field of ketamine therapy does not come without certain challenges. Given that the use of ketamine for mental health conditions and chronic pain is considered “off label” by the FDA, many third-party payers have been hesitant to cover ketamine despite the fact that it is supported by almost two decades of medical research. That being said, Klarisana has taken the lead by switching to more cost-effective intramuscular administration that is equally effective and has fewer side effects. We also now participate with Colorado and Texas Medicaid as well as many private insurance companies for integrations and other behavioral health services.